Cold agglutinin disease (CAD) was the likely trigger of repeated mini-strokes in an 84-year-old woman with already compromised blood flow in the brain due to severe narrowing of a major artery that supplies blood to the brain, according to a case report from Portugal. The underlying mechanisms of red…
News
Researchers said a case of cold agglutinin disease (CAD) in a 92-year-old man in Pakistan illustrates the challenges of CAD diagnosis and management in developing countries. The man’s experience highlights “the urgent need to improve healthcare infrastructure and enhance diagnostic capabilities while facilitating equitable access to essential CAD treatments…
The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin disease (CAD), are now expected in early 2025, the company has announced. That trial is testing a new tablet formulation of the oral therapy in people with CAD. Earlier this…
Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…
Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…
Zydus Lifesciences’ desidustat eases the anemia and red blood cell destruction that mark autoimmune hemolytic anemia, or AIHA, a group of autoimmune conditions that includes cold agglutinin disease (CAD), a study in a mouse model has found. The oral therapy was shown to stimulate red blood cell production…
Parsaclisib, an experimental oral therapy from Incyte, safely and effectively increased levels of hemoglobin in about half of people with cold agglutinin disease (CAD) in a small Phase 2 clinical trial, a study shows. Data from the study (NCT03538041), which included people with other forms of autoimmune…
Restarting Enjaymo (sutimlimab) after stopping it for up to four months was generally safe and brought blood markers of cold agglutinin disease (CAD) back to levels before its cessation. These are the findings of a Japanese open-label extension (OLE) study wherein seven CAD patients who completed one of…
Recordati agreed to acquire the global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease (CAD), from Sanofi. “With a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients…
Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…
Recent Posts
- Questions about cold sensitivity helped doctors suspect CAD in older woman
- Valuing others makes me feel visible and lifts me out of my CAD depression
- Short-term treatment may rapidly control hemolysis in secondary CAD
- Church service helps guide this CAD patient from sluggishness to strength
- For whom the bell at the treatment center rings, it rings not for me